Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment.

Yasuaki Hirooka,Yuji Nozaki,Asuka Inoue, Jinhai Li,Toshihiko Shiga,Kazuya Kishimoto,Masafumi Sugiyama,Koji Kinoshita,Masanori Funauchi,Itaru Matsumura

Bone Reports（2020）

引用 14|浏览9

暂无评分

摘要

•We compared the effects of denosumab and teriparatide on BMD in GIO patients with prior bisphosphonate treatment.•At 24 months, teriparatide increased lumbar spine and femoral neck BMD, whereas denosumab increased lumbar spine BMD only.•At 12 months, teriparatide increased lumbar spine and femoral neck BMD more than denosumab.•Teriparatide might have some advantages over denosumab in GIO patients with prior bisphosphonate treatment.

查看译文

关键词

Glucocorticoid-induced osteoporosis,Bisphosphonate,Denosumab,Teriparatide,Bone mineral density

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要